Popular Longevity Supplement Fails to Meet Endpoint in Parkinson's Trial
(MedPage Today) -- Nicotinamide riboside, a form of vitamin B3 that increases cellular levels of nicotinamide adenine dinucleotide (NAD+), had no significant clinical benefit in early Parkinson's disease, the NOPARK randomized trial showed. Commonly...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.